# Targeting Endoplasmic Reticulum Stress in Human Hypertension

> **NCT06025630** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of North Texas Health Science Center** · enrollment: 70 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** TUDCA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06025630
- **Lead sponsor:** University of North Texas Health Science Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-15
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06025630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06025630, "Targeting Endoplasmic Reticulum Stress in Human Hypertension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06025630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*